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Summary Tamoxifen and 4-OH tamoxifen were used to reverse multidrug resistance (MDR) in CHO cells
with acquired resistance to adriamycin (CHO-Adr9). Because alpha 1 acid glycoprotein (AAG) can bind a
range of calcium channel blockers that also reverse MDR and rises in malignancy, its interactions with
tamoxifen and 4-OH tamoxifen were also studied. Tamoxifen decreased the IC50 of 10O iM adriamycin 4.8-fold
in the parent CHO-KI cell line and 16-fold in CHO-Adrr. Similarly 4-OH tamoxifen decreased the IC5, 3-fold
in the parent cells, but 13-fold in the resistant cells. Tamoxifen and 4-OH tamoxifen were similarly potent in
reversing MDR, although their anti-oestrogen potency differs 100-fold. AAG was added in increasing
concentrations to the combination of adriamycin and tamoxifen. As AAG concentrations increased from 0.5
to 2 mg ml-' (the range found in vivo) the effect of tamoxifen on reversing MDR was gradually decreased. At
the highest AAG concentrations, there was complete reversal of the effects of both tamoxifen and 4-OH
tamoxifen. AAG was found to bind 3H-tamoxifen in a non-saturable non-specific manner, in contrast to the
binding of tamoxifen to albumin. Thus the use of tamoxifen as a reversal agent for MDR in vivo may be
impaired by high binding to AAG. However, at the lower range of normal values of AAG, there was still an
effect of 1O grm tamoxifen. It may be desirable to select patients for modifier studies based on AAG plasma
levels.
Development of resistance to cytotoxic cancer chemothera-
peutic agents is a major impediment to effective treatment of
human neoplastic diseases. To study this problem, in vitro
models of the multidrug resistance (MDR) phenotype have
been described where simultaneous cellular-resistance to a
number of structurally and functionally unrelated 'natural'
anticancer drugs occurred, following exposure to increasing
concentrations of a single agent (Biedler et al., 1970). Such
multidrug resistance is associated with a decrease in intracel-
lular drug accumulation attributed to a decreased rate of
drug influx (Fojo et al., 1985) and/or an enhanced rate of
efflux (Dano, 1973; Inaba et al., 1979) or both. The MDR
phenotype has been shown to result from increased expres-
sion of a gene designated mdr (Gros et al., 1986) which is
transcribed on to a 4.5-5.0 kb mRNA and the resultant
protein product is the 170,000 dalton P-glycoprotein. The
concomitant overexpression of P-glycoprotein has been con-
sistently found in different MDR human (Rogan et al., 1984)
and animal cell lines (Kartner et al., 1983, 1985).
Modulation of MDR in vitro has been demonstrated by
several compounds such as verapamil and other calcium
channel blockers (Tsuruo et al., 1981), calmodulin inhibitors
(Tsuruo et al., 1982), amiodarone (Chauffert et al., 1986) and
perhexilene maleate (Ramu et al., 1984a). The biochemical
basis for some modulators of MDR is their ability to act as a
substrate for the active efflux pump mediated by P-glyco-
protein, competitively inhibiting the efflux of cytotoxic drugs
which bind to P-glycoprotein, and thereby decreasing multi-
drug resistance (Safa et al., 1987).
A particular problem of using modulators of MDR clini-
cally, is the inability to achieve plasma levels which are
effective in reversing MDR in vitro without adverse side
effects. For example, verapamil is effective in reversing MDR
in vitro at concentrations 2.2 t1M, but maximal effect is seen
between 5 and 10 M. However, maximum achievable levels
of verapamil without major side-effects are 5 gM (Benson et
al., 1985). In addition, as verapamil binds substantially to
alpha 1 acid glycoprotein (AAG), an acute phase plasma
protein which increases non-specifically in cancer patients
(Paxton et al., 1983), the reversal of MDR by verapamil can
be attenuated by the addition of AAG (Chatterjee et al., in
preparation).
We were therefore interested in studying compounds where
(a) reversal of multidrug resistance was possible, (b) concen-
trations of drug needed to reverse MDR in vitro were
achievable in vivo, and (c) minimal or no binding to AAG
occurred.
We have studied the effect of tamoxifen, an anti oestrogen,
on suppression of adriamycin resistance. Ramu et al. (1984b)
have shown that tamoxifen can reverse multidrug resistance
in P388/Adr murine leukaemia cells. (Clinically, a daily
administration of tamoxifen 20 mg twice daily has been
shown by Patterson (1981) to have plasma levels in the range
of 450 ng ml-' (1.2tsM) after 12 weeks of treatment.) We
have recently observed that high dose administration of
tamoxifen (320 mg day-') produced plasma levels of up to
5lM. Tamoxifen is 99% bound to albumin (Adam, 1981)
and no binding with AAG has been reported. Since studies
done in cell culture models of MDR are maintained in AAG
free medium, we were interested in assessing tamoxifen
induced reversal of multidrug resistance in the presence of
AAG.
Tamoxifen is metabolised extensively and one of the major
metabolites of tamoxifen is 4-hydroxy tamoxifen, which has a
100-fold greater binding affinity for oestrogen receptor and is
a more potent anti-oestrogen than tamoxifen (Robertson et
al., 1982; Jordan et al., 1977). We therefore wanted to assess
the potential of 4-hydroxy tamoxifen as a modulator of
adriamycin resistance.
Materials and methods
Drugs
Adriamycin formulated for clinical use was obtained from
Farmitalia, tamoxifen and 4-hydroxy tamoxifen from ICI
(UK). Adriamycin was dissolved at 2 mM in water and ali-
quots stored at -20C. Tamoxifen and 4-hydroxy tamoxifen
were dissolved in 95% ethanol at 10 mM and stored at 4°C.
Ethanol at the final concentration present did not affect cell
growth. Dilutions ofdrugs were made in growth medium and
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prepared just prior to use. 3H-tamoxifen (sp. activity 82 Ci
mmol-') was obtained from New England Nuclear. Other
chemicals were obtained from the Sigma Chemical Company.
Cell and culture conditions
A CHO-Adrr cell line was isolated from wild-type (CHO-K1)
cells by exposure to progressively increasing doses of adria-
mycin up to a maximum of 0.4figml-'. Both cell lines were
maintained in Hams FIO medium (Northumbria Biologicals)
supplemented with 5% newborn calf serum, 5% fetal calf
serum, antibiotics (streptomycin 100figml-', penicillin 100
units ml-'), nystatin 50 units ml-' and 3 mM glutamine. Cells
were maintained as monolayer cultures at 37°C under 5%
CO2. The CHO-Adri mutant was stable and maintained in
drug-free medium. The CHO-Adrr mutant selected with
adriamycin was simultaneously cross-resistant to vinca alka-
loids, daunomycin, actinomycin D and colchicine, and has
amplification of mdr sequences, high mdr expression by
immunochemistry and high mRNA compared with the
parent cell line.
Quantitation ofdrug effects
Drug sensitivity was assessed by a semi-automated colorimet-
ric MTT assay, (Carmichael et al., 1987). Briefly, cells were
seeded on 96-well plates. Appropriate drug concentrations
were added for 24 h, after which the cells were washed twice
with phosphate buffered saline before being placed in 200fil
fresh medium for a further 48 h, 0.1 mg (50gAl of 2 mgml-')
MTT was added to each well and incubated at 37C for 4 h.
The medium was then carefully aspirated, crystals solubilised
in 100 gAl of dimethyl sulphoxide. Absorbences at 540 nm
were immediately read on an ELISA multiskan reader. The
IC5o was defined as the concentration of drug which caused
50% reduction in absorbance. The fold decrease in IC50
following addition of tamoxifen or 4-hydroxy tamoxifen was
determined by dividing the IC50 for the adriamycin treated
cells by that of adriamycin plus tamoxifen/4-hydroxy tamox-
ifen treated cells. A series of controls showed that cell
numbers were linearly related to absorbance in the range
5 x 103 to 4 x 104, both in the presence and absence of
adriamycin and tamoxifen. This absorbence was used in
subsequent experiments.
Tamoxifen binding to AAG or albumin
To measure binding to tamoxifen to AAG, increasing
amounts of unlabelled tamoxifen (0-40gM) plus 3H-labelled
tamoxifen (100,000 c.p.m.) were incubated with 1 mg ml-'
AAG for I h at 20°C. The reaction was terminated and
unbound tamoxifen removed by addition of 0.4 ml of char-
coal-dextran solution (0.5% w/v charcoal; 0.05% w/v dex-
tran) for 15 min at 4°C. The solution was then centrifuged
(4,000 r.p.m.) for 5 min at 4°C. Aliquots of 0.5 ml from the
supernatant were counted on a scintillation counter. Non-
specific binding in the absence of AAG was less than 2%. To
assess the binding of tamoxifen in cell-culture medium, bind-
ing to 4mgml-' albumin, which corresponded to 10%
serum, was measured as above.
To measure the rate of binding, unlabelled tamoxifen,
10 gAM and 3H-labelled tamoxifen (100,000 c.p.m.) was incu-
bated with 1 mg mlI AAG for varying time intervals and
measured as above.
Drug accumulation studies
Exponentially growing cells were harvested by gentle agita-
tion in 0.02% EDTA in PBS, washed by centrifugation and
resuspended (1 x I07 cellsml-') in PBS, pH 7.4, containing
1% BSA and 10 mm glucose. Aliquots of 100gAl of cells were
preincubated for 10 min at 37°C. At time zero, 100 glI of
medium containng 1 gAM adriamycin, with or without 1OgM
tamoxifen, was added and incubated for varying time inter-
vals. Influx was stopped by adding 4ml of ice-cold buffer
(PBS containing 1% BSA), following by centriguation (3,000
r.p.m. x 10 min). The cells were washed twice with ice-cold
buffer before the final cell pellet was solubilised in 1% SDS,
10 ml of liquid scintillant was added and radioactivity count-
ed on a scintillation counter.
Statistics
Unpaired t tests were used to compare data points. Where
differences are stated in the text there were significant at
P<0.05 or higher degrees of significance. In all figures error
bars are shown unless they fall within the size of the symbol.
Results
Effect oftamoxifen and 4-hydroxy tamoxifen on CHO-J and
CHO-Adrr cells
To examine the sensitivity of the CHO-K I and CHO-Adrr
cells to tamoxifen and 4-hydroxy tamoxifen, the cells were
exposed to appropriate drug concentrations for 24 h (Figure
la). The IC5o of tamoxifen is 21 gAM in the CHO-KI cells and
22.5 tLM in the CHO-Adrr cells. Similarly, the IC5o of 4-
hydroxy tamoxifen is 26tLM in the CHO-K1 cells and 24 gLM
in the CHO-Adrr cells (Figure Ib). Therefore, both cell lines
demonstrate similar sensitivity to the parent drug tamoxifen
and its metabolite 4-hydroxy tamoxifen. To assess whether
the presence of AAG could alter the cytotoxicity of tamoxi-
fen and 4-hydroxy tamoxifen, 2 mgml' AAG was added.
With the addition of 2 mg ml-' AAG to increasing concen-
trations of tamoxifen, the cells were completely protected and
cell survival in both cell lines was increased to 80-100% of
control. With 4-hydroxy tamoxifen, 2 mgml-' AAG did not
cause such a marked effect and the IC5o was decreased only
1.4-fold in CHO-KI cells (P<0.05) and 1.3-fold in the
CHO-Adrr cells (P<0.05). Therefore, the parent compound
and its metabolite interact with AAG to different extents.
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Figure 1 Effect of increasing concentrations of (a) tamoxifen
and (b) 4-OH tamoxifen in CHO-KI (@-@, 0-0) and
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Tamoxifen binding to AAG
To study the binding of tamoxifen to AAG, increasing con-
centrations of tamoxifen were incubated with either 1 mg
ml' AAG or 4mgmlhl albumin (corresponding to 10%
serum). Increased binding of tamoxifen to 1 mgml' AAG
occurred with increasing concentrations of tamoxifen (Figure
2). At the highest concentration of 40JAM, 30 nmolml' are
bound to AAG. The binding is non-specific and non-satur-
able. It occurs rapidly and is temperature-independent
(Figure 3). In contrast, with 4mgml-' albumin maximum
binding of tamoxifen was 7.5 nmol ml-' and was saturable
(Figure 2).
Effect oftamoxifen on adriamycin cytotoxicity
Increasing concentrations of tamoxifen (1, 5 and 10JiM ) that
had little or no effect on cell growth enhanced the ability of
adriamycin to inhibit cell growth in both cell lines (Figure
4a). The IC5o of adriamycin in CHO-Ki cells in the absence
of tamoxifen was 0.24gM. With the addition of 1, 5 and
10JAM tamoxifen, the IC,o was decreased and the correspond-
ing decrease was 1.8-fold, 2.4-fold and 4.8-fold respectively.
In the CHO-Adr' cells, the IC5o of adriamycin was 6.4gM,
and a 26-fold resistance to adriamycin was present. The
addition of 1, 5 and 10JM tamoxifen increased the chemo-
sensitivity ofadriamycin and the decrease in the IC50 was 2.1,
4.0 and 16-fold respectively (Figure 4b). The shift in the
aborbence curves to the left with increasing tamoxifen con-
centrations was greater in the CHO-Adr' cells than in the
CHO-Kl cells. At the highest concentration of 10gM tamox-
ifen, a residual 2-fold resistance in the IC,o of adriamycin
remained in the CHO-Adrr cell line, compared to the IC50 of
adriamycin alone (0.2gJM) in the CHO-KI cell line.
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Figure 2 Measurement of binding of tamoxifen (0-40JAM) to
mgml- AAG ( -0) or 4mg ml-I albumin (O-0). Each
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Figure 4 a, Sensitivity of CHO-KI cells to adriamycin in the
absence ( -0) and presence of I JAM (O-0), 5jAM (0-0)
and 1OgM (U -U) tamoxifen. Each point represents the mean
±s.e. of at least three experiments. b, Sensitivity of CHO-Adrr
cells to adriamycin in the absence (A -A) and presence of I JiM
(A A), 5AM (0-0) and IOgM (U-U) tamoxifen. Each
point represents the mean±s.e. of at least three experiments.
Effect of4-hydroxy tamoxifen on adriamycin cytotoxicity
To determine the effect of non-toxic concentrations of 4-
hydroxy tamoxifen on adriamycin cytotoxicity, 5 AM or
10iJM 4-hydroxy tamoxifen was added to increasing adria-
mycin concentrations. In both CHO-KI and CHO-Adrr cell
lines, the addition of4-hydroxy tamoxifen shifted the absorb-
ance curve to the left, the shift being greater in the CHO-
Adrr cells. In CHO-KI cells, the ICo of adriamycin was
decreased 2.4 and 3.0-fold with 5JAM and 10IJM 4-hydroxy
tamoxifen respectively (Figure 5a), whereas in the CHO-Adrr
cells the lC5( of adriamycin was decreased 2.0 and 13-fold
with a similar concentration of JiM 4-hydroxy tamoxifen
(Figure Sb). A 2-fold resistance to adriamycin remained with
the highest concentration of 4-hydroxy tamoxifen, compared
to the ICo ofadriamycin alone (0.23JAM) in the CHO-KI cell
line.
Effect oftamoxifen on intracellular accumulation of
adriamycin
To evaluate whether the potentiation of adriamycin cyto-
toxicity by tamoxifen could be attributed to increased
accumulation of adriamycin, both cell lines were incubated
with '4C-adriamycin for various time periods and levels of
intracellular adriamycin measured.
Over a 120min incubation period, there was a 1.5-2-fold
lower amount of adriamycin in the CHO-AdrT cell line com-
pared to the parental cell line (Figure 6a versus b, P<0.05).
The addition of 1OJM tamoxifen caused very small increases
in drug levels in both cell lines (not significant).
Effect ofAAG onpotentiation ofadriamycin cytotoxicity by
tamoxifen and4-hydroxy tamoxifen
Since tamoxifen and 4-hydroxy tamoxifen potentiated adria-
mycin cytotoxicity in CHO-KI and CHO-Adrt cell lines, we
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of at least three experiments. b, Sensitivity of CHC
adriamycin in the absence (A A) and prese
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The CHO-Adr cell line is 28-30-fold resistant to adriamycin,
but both cell lines demonstrate equal sensitivity to tamoxifen
and 4-hydroxy tamoxifen, which suggests that different cyto-
toxic targets exist. 4-hydroxy tamoxifen has a 100-fold higher
anti-oestrogen activity than tamoxifen, but its cytotoxicity is
similar to tamoxifen. Therefore, we have concluded that the
p potentiating effect is independent of the oestrogen receptor
T \ status (no oestrogen receptors detectable by ligand binding
were present in the two cell lines; results not shown). Since
the cytotoxicity of 4-hydroxy tamoxifen was relatively unal-
tered by AAG compared to tamoxifen (Figure 1 and 2), it
could be suggested that elevated AAG concentrations in vivo
would cause less change in 4-hydroxy tamoxifen-mediated
20 growth inhibition compared to tamoxifen. However, this
effect was only demonstrated at toxic tamoxifen or 4-OH
tamoxifen concentrations of greater than 1OYtM, which are
higher than those used for resistance modification.
We have also demonstrated in this study that the sen-
sitivity to adriamycin in a MDR mutant (CHO-Adrr) can be
increased by tamoxifen or its metabolite 4-hydroxy tamoxifen
at concentrations which do not inhibit cell growth on their
\, own. The degree of potentiation was greater in the CHO-
A Adrr cell line than in the parent cell line, which is compatible
with low degrees of mdr expression in the CHO-Ki cell line.
A This is similar to results with other modulators of MDR. The
exact mechanism ofmodulation of adriamycin cytotoxicity is,
however, unclear.
Reddel et al. (1985) have demonstrated that the growth
inhibitor effect of tamoxifen is oestrogen-irreversible at high
5.0 10.0 concentrations and they suggest the possibility of oestrogen-
noncompatible, anti-oestrogen-specific binding sites (AEBS)
(Sutherland et al., 1980; Miller & Katzenellenbogen, 1983).
amycin in the Ramu et al. (1984) have demonstrated reversal of MDR by
), and 10 1M triparonol analogues such as tamoxifen, clomiphene, nafoxi-
ie mean ± s.e. dine (but not 4-hydroxy tamoxifen). They suggest that the
)-Adrr cells to
nce of 51M
point repre- a
sents the meants.e. oi at least tnree experiments.
assessed the effect of the addition of AAG in a concentration
range present in cancer patients (Paxton, 1983). Both cell
lines were accordingly exposed to equitoxic concentrations of
adriamycin, in that concentration which reduced cell viability
to 80-90% of control. Therefore, CHO-KI cells in the pres-
ence of an increasing concentration range of AAG (0-2 mg
ml-') were exposed to 0.05 lM and CHO-Adrr cells to 1 gM
adriamycin in the absence or presence of 10 gAM tamoxifen or
4-hydroxy tamoxifen.
In CHO-KI cells (Figure 7a), adriamycin at 0.05 J1M
decreased cell viability to 86% of control and addition to
10 iM tamoxifen decreased it further to 37% of control. In
CHO-Adrr cells, the cell viability was 82% of control in the
presence of 1 t.M adriamycin and was decreased to 44% of
control with the addition of 101JM tamoxifen. The addition
of AAG (0-2 mg ml-') resulted in a gradual increase in cell
viability, and finally, at 2 mg ml-' AAG, cell viability was
similar to that of cells exposed to adriamycin alone.
Similarly, when 10JM 4-hydroxy tamoxifen was added to
adriamycin, cell viability was decreased to 35% of control in
CHO-KI cells and 35% of control in CHO-Adrr cells (Figure
7b). Addition of AAG increased cell survival and at the
highest AAG concentration (2 mg ml-'), there was no signi-
ficant difference in the cell viability of cells treated with
adriamydin alone versus cells treated with adriamycin, 4-
hydroxy tamoxifen and AAG. AAG did not independently
affect cell growth or adriamycin cytotoxicity (results not
shown). However, at concentrations of AAG < 1 mg ml'
potentiation was still detectable.
Discussion
We have demonstrated a cytotoxic effect of tamoxifen and
4-hydroxy tamoxifen in the sensitive and resistant cell line.
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increased membrane rigidity reported in MDR cell mem-
branes was decreased by the triparonol analogues, which
accounted for faster diffusion of adriamycin and enhance-
ment of its cytotoxicity. Foster et al. (1988) have reported
modulation of drug resistance in a MDR, MCF-7 breast
cancer cell line with 10 gAM tamoxifen or perhexilene maleate.
Since the addition of 50 nM oestradiol did not attenuate the
effects of tamoxifen, they have suggested that reversal of
MDR by tamoxifen is not oestrogen-dependent. However,
there was no increase in '4C-adriamycin accumulation, raising
the possibility that tamoxifen modulates MDR by mechan-
isms other than increasing intracellular accumulation of the
anticancer drugs to which the cell line is resistant. Kessel
(1986) has studied the relationship between membrane trans-
port systems involved with adriamycin, calcium antagonists
(verapamil and nitrendipine) and anti-oestrogens (tamoxifen)
in their circumvention of multidrug resistance. He concluded
that no common exodus system can explain the effects of
calcium antagonists and anti-oestrogens, both modulators of
MDR. Thus these drugs modulate MDR by different mem-
brane interactions. Yang et al. (1989) have demonstrated
progesterone binds to P-glycoprotein, enhances drug accum-
ulation and sensitivity of MDR cells to vinblastine. Their
study also revealed that a and ,-oestradiol do not bind to
P-glycoprotein. Tamoxifen possibly does not bind to P-glyco-
protein but reverse MDR by a P-glycoprotein independent
mechanism. We have shown a 15-fold reversal in adriamycin
cytotoxicity by 10 LM tamoxifen in CHO-Adrr cells (Figure
4b) but no significant increase in adriamycin accumulation
with 10 LM tamoxifen (Figure 6b), which suggests that in-
creased drug uptake is probably not one of the mechanism(s)
by which tamoxifen reverses MDR.
Protein kinase C (PKC) is a high affinity phorbol ester
receptor. Phorbol esters and other tumour promoters func-
tion by acting as diglyceride substitutes and active PKC in
vitro and in vivo. PKC is believed to transduce a variety of
growth promoting signals and may have an important role in
tumour promotion. The importance of PKC is regulation of
cell growth suggests that PKC inhibitors could prove to be
effective anti-proliferative agents. O'Brian et al. (1988) have
reported (a) inhibition of rat PKC activity in vitro by tamox-
ifen and its principal metabolites 4-hydroxy tamoxifen and
desmethyl tamoxifen, mediated by the compounds binding to
the catalytic domain of the enzyme and (b) the inhibitory
potencies against PKC activity correlate with the oestrogen
irreversible cytotoxic effects shown in the MCF-7 cell line.
Horgan et al. (1986) have shown inhibition of PKC activity
in vivo by tamoxifen. These results, therefore, suggest that
inhibition of PKC may play an important role in the anti-
tumour effect and modulation of MDR by tamoxifen and
4-hydroxy tamoxifen.
Another more likely target is calmodulin since the IC5o of
tamoxifen is only 2gM for this enzyme (Lam, 1984) com-
pared with 25tLM for IC50 of 4-hydroxy tamoxifen on PKC
(O'Brian et al., 1988).
AAG, which is normally absent from cell culture medium,
has been shown to reverse the effect of verapamil-induced
potentiation of adriamycin cytotoxicity (Chatterjee et al., in
preparation). Verapamil binding to AAG has been shown by
Gillis et al. (1985). Since tamoxifen was reported to be 99%
bound to albumin (Adam, 1981) and binding to AAG had
not been suggested, we wanted to assess whether AAG, when
present, could alter the reversal of adriamycin resistance by
tamoxifen or 4-hydroxy tamoxifen. Our results have shown
that AAG present at concentrations found at the higher
range in cancer patients (0.8-2.0mgml-') can attenuate the
reversal of multidrug resistance. However, AAG at levels
found in the normal population and at the lower end of the
cancer population allowed for enhancement of adriamycin
cytotoxicity by the modulators used. Lien et al. (1989) recent-
ly reported that tamoxifen is bound mainly to albumin, but
only assessed binding of approximately 40 nM tamoxifen. In
our study, 250-fold higher levels were used and it is clear that
at these levels AAG markedly modifies the effects of tamox-
ifen and tamoxifen binds to AAG in the presence of albumin.
There was a residual 3-fold resistance of the CHO-Adrr
mutant to adriamycin in the presence of tamoxifen. Recent
studies have shown it is possible to increase the dose of
adriamycin more than 2-fold, provided marrow is supported
by haemopoetic growth factors (Bronchud et al., 1989). Thus,
a combined approach may be able to reverse resistance
clinically. Although normal tissues may also be sensitised, the
relatively greater effects of reversal agents on resistant cells
with high levels of expression may still enhance the thera-
peutic/toxic ratio of anthracycline.
Possible clinical implications of this study are that tamox-
ifen and 4-hydroxy tamoxifen could prove effective cytotoxic
agents as well as modulators of multidrug resistance; the
limiting factor to their effectiveness could be high levels of
AAG. It is conceivable that the free fraction of tamoxifen
diffuses into tissues over several days to weeks and accum-
ulates there, to exert its anti-oestrogen effect. Although 4-
hydroxy tamoxifen is a minor metabolite of tamoxifen, it is
much more potent (Jordan et al., 1977). It has a lower degree
of AAG binding, as assessed from the lack of protection by
AAG against 4-hydroxy tamoxifen toxicity. Thus in vivo it
may be a major component of the biological anti-oestrogen
effect. Clinical trials with the addition of tamoxifen in a
chemotherapy regimen could increase the therapeutic index
of the anticancer agents, in tumours without oestrogen recep-
tors. It would be appropriate to select patients with low
AAG levels for such studies.
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